The outbreak of the corona virus disease 2019 (COVID-19) pandemic has led to an unprecedented pressure on the global health sector, with the sub-Saharan African countries as well as other developing countries being among the most hit (Chen et al., 2020; Willan et al., 2020). The disease which originated from Wuhan China in December 2019 as cluster crises of pneumonia, is caused by the novel β-coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 popularly regarded as SARS-CoV-2.

Italy, the United Kingdom and Spain were the epicenters for the pandemic in Europe, United States for North America, Brazil for South America, and South Africa for Africa. Although the cases of COVID-19 and mortality rate is lower in African countries compared to other continents, the pandemic has caused a lot of pressure on the poor health systems and economies of these countries which were already burdened with existing non-communicable diseases particularly malaria, AIDS and tuberculosis (Hogan et al., 2020; Sands, 2020; Sherrard-Smith et al., 2020). These setbacks coupled with an uncontrolled growing population exacerbates the continent’s vulnerability to the pandemic with major consequences. Egypt was the first to announce a case in the continent on February 14, 2020, this was followed by Nigeria on February 27, 2020, while South Africa announced her index case on March 5, 2020 (Lone and Ahmad, 2020; Zhao et al., 2020). These figures have so far grown to over 6 digits with South Africa presently having the highest cases. It is pertinent to mention that the virus was brought into the continent by travelers from Europe and has so far led to community spread.

The absence of a substantial standard protocol treatment and vaccine for the disease have led to continuous efforts by scientists and policy makers to curb the disease spread through mainly non-pharmaceutical interventions. These efforts include public sensitization on the virus and the disease, testing, patient isolation and contact tracing, as well as implementation of government policing such as national lockdown, social and physical distancing, mandatory public use of face mask, and constant washing of hands (Mitjà and Clotet, 2020). Despite South Africa passing some of the world’s stringent lockdown rules to curb the transmission of the virus, it has experienced an exacerbated growth in the number of cases which have caused tremendous strain on her health care system and economy. This has led to the search of novel and cheaper alternatives for the treatment of the diseases, with much attention given to indigenous medicinal plants. This has also led to the African stance through the WHO afro, Africa-CDC and the AU Commission in setting up an expert committee on traditional medicines for COVID-19 which aims at strengthening African countries by finding traditional medicines for the disease.

Several studies have reported the potentials of medicinal plants in the treatment and management of COVID-19 and its complications (Benarba and Pandiella, 2020; Erukainure et al., 2020; Vellingiri et al., 2020). These therapeutic properties have been attributed to the phytochemical constituents of the plants. Amongst these plants is Cannabis sativa.

Cannabis sativa is a member of the Cannabis genus and the Cannabaceae family. It is an annual herbaceous plant commonly known as weed, marijuana, Indian hemp, weed and dagga in different parts of the world. Its utilization cuts across religious and recreational purposes, as well as traditional medicine and food (Kuddus et al., 2013; Bonini et al., 2018). The plant is now the most reported for its pharmaceutical medical uses and it is regarded as a global specie as it is widely distributed across the world (UNODC, 2012). Although its utilization is under strict rules in most countries, C. sativa has over the years been reported to be effective in the treatment and management of several ailments such as diabetes mellitus (Ren et al., 2016), different cancer types (Guzman, 2003), insomnia (Ramar et al., 2018), epilepsy (Fusar-Poli et al., 2009), severe pains (Whiting et al., 2015) and neurodegeneration (Aso and Ferrer, 2016). These medicinal properties have been attributed to the phytochemical constituents of C. sativa, particularly the phytocannabinoids. Cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabinol (CBN) constitute the predominant phytocannabinoids in C. sativa (Andre et al., 2016), and have been studied widely for their medicinal applications.

Recently, C. sativa has been gaining interests as a possible therapy for the treatment of COVID-19 and its complications (Byrareddy and Mohan, 2020; Mabou Tagne et al., 2020). This has been attributed to the antiviral activities of its phytocannabinoids such as CBD against hepatitis C and Kaposi sarcoma (Mabou Tagne et al., 2020), as well as its potent anti-inflammatory properties as depicted by its ability to suppress the production of TNF-α, MIP-1a, IL-2, 6, 1α and 1β, MCP-1, and interferon gamma (Nichols and Kaplan, 2020). These proinflammatory cytokines have been implicated in the pathogenesis and progression of COVID-19 induced by SARS-CoV-2 via the cytokine release syndrome (CRS) (Mehta et al., 2020; Nichols and Kaplan, 2020; Shi et al., 2020) commonly regarded as the cytokine storm. Therefore, studying the potentials of C. sativa and its phytocannabinoids as a possible therapy in the treatment and management of COVID-19 will contribute to the curbing of the disease.

This study aimed at decoding the possible evolutionary trend of COVID-19 in South Africa by comparing the genome of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa with those isolated from China, Spain, Italy and United States, as well as the genomes of Bat SARS CoV, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Mouse Hepatitis Virus (MHV), and Infectious Bronchitis Virus (IBV). The study also investigated the ability of identified compounds from C. sativa to interact with gene segments (mRNAs) coding for proteins implicated in viral replication, assembly and release vis-à-vis ORF1ab, Surface glycoprotein, Envelope protein and Nucleocapsid phosphoprotein from the whole genome of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa using computational tools.

Since its outbreak in Wuhan China, SARS-CoV-2 has spread across the globe leading to the COVID-19 pandemic. The spread of the disease has been attributed mostly to infected travelers who act as carrier of the virus, and then leading to community spread. In the present study, we decoded the origin of the virus in South Africa by comparing the genome of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa with those of countries with reported high cases (Table 1). The 96% homology with genomes from China, Spain Italy and United States suggests SARS-CoV-2 in South Africa originated from outside the continent and corroborates reports that her index COVID-19 case was a male citizen who tested positive to the virus after a trip to Italy (SAG, 2020). This also corroborates the global spread of the virus and the disease (Lee, 2020; Macintyre, 2020). Furthermore, the 93% homology of the genome of the South African isolate with bat SARS COVs, as well as the 92 and 94% homology with MERS-COV and MHV/IBV isolates, respectively insinuates an evolutionary conservation among the whole genomes of the studied coronaviruses. These evolutionary trends corroborate reports that suggest that coronaviruses are of bat origin (Lu et al., 2020; York, 2020; Zhou et al., 2020).

Coronaviruses are enveloped viruses with a single strand, positive-sense RNA genome of 27–32 kb in length (Liu et al., 2007). Several studies have reported more than 100 full-length or partial genomic sequences for SARS-COV-2 (Wang et al., 2020). The genome contains about six to nine sorts of mRNA, comprising the genome-length mRNA and five to eight sub-genomic mRNA which code for structural protein and many other for non-structural proteins (Liu et al., 2007). In an infected cell, coronaviruses induce the formation of double-membrane vesicles and convoluted membranes that harbor the nonstructural proteins (Verheije et al., 2010). The structural proteins include transmembrane spike glycoprotein, nucleocapsid phosphoprotein, envelope, and surface glycoproteins (Baudoux et al., 1998), whereas the nonstructural includes ORF1ab, ORF3, ORF6, ORF7a, ORF8, and ORF10 which contains information for genome RNA synthesis and replication (Tsai et al., 2020). The entry mechanism of SARS-CoV-2 starts with its transmembrane spike glycoprotein attachment to host cell membrane receptor (angiotensin-converting enzyme 2) and induce its entry through membrane endocytosis. ORF1 stimulates the virus replication and synthesis of the subgenomic RNAs, while nucleocapsid phosphoprotein packages the viral genome to form the helical nucleocapsid that is unified into the budding particle and can also function as an RNA chaperone. Envelope and surface glycoproteins induce virion assembly and morphogenesis leading to the formation of virus-like particles and the final release of the virions by exocytosis (Ho et al., 2004; Zúñiga et al., 2007; Andersen et al., 2020). Any attempt to interfere with the expression of one of these proteins could be tantamount to disrupting the overall SARS-COV-2 transmission cycle. Therefore, targeting these structural and nonstructural protein components especially at translational level of mRNAs being converted to proteins, could serve as a viable therapeutic strategy against SARS-COV-2. This is corroborated by studies which reported ORF1ab, surface glycoprotein, nucleocapsid phosphoprotein, envelope, membrane, spike protein, protease, hemagglutinin esterase and helicase as possible therapeutic target for coronaviruses including SARS-CoV-2 (Mcbride et al., 2014; Bhatia et al., 2020). The strong binding affinities of the identified compounds from C. sativa (Figure 2 and Table 3) with both the initiation and termination codons of ORF1ab, Surface glycoprotein, Envelope protein and Nucleocapsid phosphoprotein mRNAs from the whole genome of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa (Figures 3–8) therefore, portray their high potential as possible therapy for treatment of COVID-19 and its complication by curbing the replication, translation, assembly, and release of the virus. The mechanism of these strong binding affinities of the identified compounds from C. sativa againts the identified mRNA initiation and termination codons could be due some chemico-biological interactions based on the chemistry of the said bioactive compounds versus that of nucleotides. Literally, the constituents of mRNA include adenine, guanine, cytosine, uracil and a phosphate terminal (Elliott and Ladomery, 2017). Meanwhile, these chemical compounds are classified as purine and pyrimidines and are known to constitute basic functional group (amine and carbonyl) with the capacity to undergo nucleophilic or electrophilic reactions (Ulbricht, 2016). In the biological system, natural product dissociates, hence, the tendency to interact with purines and pyrimidines via electrostatic, hydrophobic, intermolecular force or covalent bond is certain. GC-MS analysis of Cannabis sativa extract revealed the presence of tetrahydrocannabivarin, cannabispiran, cannabidiol tetrahydrocannabinol, cannabigerol, and cannabinol. These compounds contain free hydroxyl and aromatic rings which confers on them the ease to interact with the purines, pyrimidines, or phosphate terminal of SARS-CoV-2 genome mRNA sequence via hydrogen bonding or intermolecular interaction. Hydrogen bond formation between the oxygen at carbon 2 of the purines on the genome of SARS-CoV-2 mRNA may be responsible for its interaction with natural product. On the other hand, the free amine attached to carbon 2 and 6 of guanine and adenine respectively may account for the mechanism of interactions (electrostatic) between pyrimidines and the natural product obtained from Cannabis sativa extract. Similarly, the phosphate terminal of the SARS-CoV-2 mRNA could electrostatically interact with the polar region of electron deficient natural product that may have dissociated with the biochemical environment. Hence, at a favourable pH within the biochemical system, natural product obtained from Cannabis sativa extract can dissociate to impart a possible therapeutic function against COVID-19. Furthermore, flavonoid-based molecules from C. sativa have also been shown to bind with high affinity to the spike protein, helicase, and protease sites on the ACE2 receptor used by the coronavirus 2 to infect cells and cause COVID-19 (Attia et al., 2020; Khanna et al., 2020).

Interestingly, the viral proteins have also been implicated in manipulating the host’s innate immune system (Alexander et al., 2019). Conversely, C. sativa and its phytocannabinoids have been proposed as a possible natural products for the treatment of COVID-19 (El Biali et al., 2020; Mckernan et al., 2020). This is also coupled with their reported potent anti-inflammatory activities esepecially CBD, tetrahydrocannabivarin and THC (Bolognini et al., 2010; Anil et al., 2020; Nichols and Kaplan, 2020) as the pathologenesis and progression of the virus have been linked to excessive producition of pro-inflammatory cytokines often termed as cytokine storm syndrome leading to suppression of the immune system (Ragab et al., 2020; Vaninov, 2020).

These results further indicate that phytochemicals from C. sativa can respond to the COVID-19 at different levels of its mRNAs and different mechanisms. They corroborate previous studies that tentatively indicated that CBD and THC may be beneficial in the treatment of patients whose bodies’ inflammatory response has become pathogenic and therefore respond to the cytokine storm (Nagarkatti et al., 2009; Onaivi and Sharma, 2020; Rossi et al., 2020). Much research in this field has focused on the ability of cannabinoids and terpenes to lower the immune system’s response without suppressing.

Taken together, the results from this study indicates a homology between the genome of SARS-CoV-2 isolated from KwaZulu-Natal, South Africa and those isolated from Europe, Asia and North America, as well as those isolated from bat SARS COV, MERS-CoV, MHV and IBV. Thus, depicting the spread of the virus is intercontinental and might have evolved from other coronaviruses. The results also indicate the phytocannabinoids of C. sativa infusion as potential therapies against COVID-19 as depicted by their ability to molecularly interact with codon mRNAs of proteins implicated in the replication, translation, assembly, and release of SARS-CoV-2. However, further studies are needed to verify these activities pre-clinically and clinically. It is also recommended that LC-MS analysis should be carried out on the infusion to further identify its polar constituents.